The mechanisms regulating the postprandial suppression of ghrelin secretion remain unclear, but recent observations in rats indicate that an increase in duodenal osmolarity is associated with a reduction in ghrelin levels. Several hormones have been implicated in the regulation of ghrelin.
T he appetite-stimulating peptide, ghrelin, is secreted from closed-type endocrine cells nested in the mucosal lining of the stomach (1, 2) . Ghrelin is thought to be involved in meal initiation; moreover, intravenous ghrelin infusions have been reported to accelerate gastric emptying, stimulate growth hormone secretion. and influence glucose homeostasis (1, 3, 4) .
Plasma ghrelin concentrations increase during fasting and decline postprandially for a few hours, before returning to preprandial levels (5) . In contrast, most other gut peptides increase after eating (6) . Whereas ghrelin concentrations in the fasted state have been shown to be modulated by vagal and cholinergic tone (7) (8) (9) , postprandial ghrelin suppression does not appear to require an intact vagal circuitry (7, 10) . Exposure of the small intestine to the ingesta is, however, required for postprandial ghrelin suppression (11) (12) (13) (14) (15) (16) (17) . Several studies have examined the effect of type (11, 15, 18, 19) , load (18, 20, 21) , and digestion (22, 23) of nutrients on postprandial ghrelin levels, but the importance of the osmolarity of small intestinal content has received little attention. This is a pertinent issue, particularly in view of the outcome of a recent study in rats (24) , where small intestinal infusions of hyperosmolar solutions of glucose, saline, lactulose, as well as the nonmetabolized glucose analog, 3-O-methylglucose, suppressed ghrelin levels, whereas isoosmolar solutions of the same solutes had no effect.
In healthy humans, plasma ghrelin concentrations have been reported to be suppressed after small intestinal infusion of hyperosmolar saline (18) , although the magnitude of the reduction was less than with glucose solutions of the same osmolarity. However, that study did not include isoosmolar saline or water controls. The reduction in ghrelin concentrations could therefore have been either a time effect, or potentially resulted from distension of the gut by the administered fluid.
Hyperosmolar stimuli are physiologically relevant, given that the enzymatic digestion of disaccharides and polysaccharides, protein, and lipid result in hyperosmolar luminal content in the proximal small intestine after meals (25) (26) (27) (28) (29) . Hyperosmolar solutions have been reported to suppress spontaneous food intake and increase water ingestion in pigs and sheep (30, 31) , to inhibit antral activity (32) , slow gastric emptying in humans (33) (34) (35) (36) , and inhibit gastric acid secretion (37, 38) , and to decrease (39) or increase (40) small intestinal motility depending on the nature of the solution. These effects might be mediated by gut peptides such as cholecystokinin (CCK) (41) , glucagonlike peptide-1 (GLP-1) (42) , and peptide YY (PYY) (43) . Gut peptides have also been proposed to mediate postprandial ghrelin suppression (44) (45) (46) . We sought to clarify the effect of osmolarity by examining ghrelin responses to small intestinal hyperosmolar vs isoosmolar infusions in healthy humans and included measurements of gut peptides, including CCK, glucose-dependent insulinotropic polypeptide (GIP), GLP-1, glucagon, PYY, neurotensin (NT), pancreatic polypeptide (PP), and motilin, because any effects on ghrelin might be secondary to hyperosmolarity-induced changes in the plasma concentrations of these peptides. ] participated in the study. Only males were recruited to avoid the potential confounding effect of the menstrual cycle on gut hormone secretion (47) .
Participants and Methods

Study ethics and participants
Study design
Each participant was studied on 2 days, separated by 7 to 14 days, in a randomized double-blind fashion. Participants were asked to maintain their usual diet and activity levels throughout the study. On the evening before each study day, participants were provided with a standardized beef lasagna meal (McCain Foods, Wendouree, VIC, Australia; 2472 kJ), to be consumed at 7:00 PM with water. Following this meal, they consumed only water until 10:00 pm, and then fasted until the following morning (13h/8h fasting for solids/liquids, respectively).
Infusions
Participants attended the clinical laboratory at the Royal Adelaide Hospital at 8:00 AM. A nasoduodenal multilumen catheter (external diameter, 3.5 mm; Dentsleeve International, Mississauga, ON, Canada) was inserted through an anesthetized nostril and allowed to pass through the stomach and into the duodenum by peristalsis. Tube position was monitored by continuous measurements of the transmucosal potential difference in the most distal antral channel (about 240 mV) and the most proximal duodenal channel (;0 mV) (23); a cannula filled with sterile saline placed subcutaneously in a forearm was used as a reference electrode. The infusion port was positioned 12 to 14 cm distal to the pylorus (48) . An intravenous cannula was placed in the cubital fossa for repeated blood sampling, and the arm was kept warm with a heated pad. Participants remained recumbent throughout the study.
Once the nasoduodenal catheter was positioned correctly, participants rested for ;15 minutes and a baseline blood sample was then drawn (t = 245 minutes). At t = 0 minutes, an intraduodenal infusion of isoosmolar (300 mOsm/L) or hyperosmolar (1500 mOsm/L) saline commenced at a rate of 4 mL/min and continued for 45 minutes (total volume 180 mL). The osmolarity of the hyperosmolar solution was comparable to that given in an oral glucose tolerance test (75 g of glucose in 300 mL, ;1400 mOsm/L) and to solutions employed previously to evaluate the effects of intraduodenal glucose on gut hormone secretion (18, 49) .
Blood sampling
Arterialized venous blood (12 mL) was sampled at t = 245, 230, 215, 0, 15, 30, 45, 60, 75, 90, 120, and 180 minutes and placed into iced EDTA tubes (Sarstedt, Nümbrecht, Germany) for subsequent peptide measurements, and into sodium fluoride tubes for plasma glucose analysis. Samples were centrifuged at 4°C for 15 minutes at 1946 3 g (;3200 rpm, Heraeus Multifuge 1S-R; Thermo Fischer, Asheville, NC) and stored at 280°C until analyses.
Appetite and gastrointestinal perceptions
Hunger, desire to eat, prospective food consumption, thirst, nausea, and fullness were assessed using 100-mm visual analog scales (VASs) (50) at the same time points used for blood sampling.
Peptide and glucose analyses
• Ghrelin: Total plasma ghrelin was measured in duplicate using the Millipore HK-89 total ghrelin radioimmunoassay (RIA) kit (Millipore, Billerica, MA).
• GLP-1: Total plasma GLP-1 was measured using an inhouse RIA employing an antibody (89 390) with an absolute requirement for the intact amidated C-terminus of GLP-1, which measures both intact (active) and N-terminaltruncated forms of GLP-1 (8).
• GIP: Total plasma GIP was measured using an in-house RIA employing a C-terminal-directed antiserum (80 867) (8).
• NT: Total plasma NT was measured with an in-house RIA employing an N-terminal-specific antibody (3D97) (51).
• CCK: Total plasma CCK was measured by RIA using antiserum code no. 92128, which binds the circulating bioactive forms of CCK with equal potency, and without cross-reactivity with homologous gastrin peptides (52).
• PP: Total plasma PP was measured using a midregionspecific antibody (HYB 347-07) (Statens Serum Institut, Copenhagen, Denmark) (8).
• Glucagon: Plasma glucagon was measured using the C-terminal-directed antiserum (4305), which detects glucagon of pancreatic origin (8).
• Motilin: Plasma motilin was measured by an in-house RIA using the antibody code no. 8422 (53).
• PYY: Total plasma PYY was measured in duplicate using an RIA kit [PYYT-66HK, human PYY (total) RIA, Millipore].
• Glucose: Glucose levels in plasma were measured by the glucose oxidase method using a glucose analyzer YSI 2300 Stat Plus (Yellow Springs Instruments, Yellow Springs, OH).
Blood pressure and heart rate
Blood pressures and heart rate were recorded using an automated blood pressure cuff (DINAMAP ProCare 100; GE Medical Systems, Milwaukee, WI) every 5 minutes during the study period (from t = 245 to 180 minutes).
Outcome measures
The primary endpoint was the change in plasma ghrelin concentrations associated with small intestinal infusions of isoosmolar and hyperosmolar saline. Secondary endpoints were changes in concentrations of other gut peptides, gastrointestinal sensations (including hunger, satiety, and prospective food intake), and cardiovascular parameters (i.e., heart rate and blood pressure).
Statistical analyses and calculations
Based on previous studies (18, 24) , we anticipated that 18 participants would at least provide 80% power (at a = 0.05) to detect a 40% difference in the area above the curve for plasma ghrelin (primary outcome) and allow conclusions to be drawn from the VAS evaluations of hunger and satiety (54) .
Participant characteristics are reported as means and SDs, whereas outcome measures are expressed as means and SEMs. Plasma glucose and peptide hormone levels were analyzed by two-factor repeated-measures ANOVA with time and treatment as factors. When relevant, post hoc testing was performed using the Bonferroni correction. P , 0.05 was considered statistically significant. Statistical analyses were performed using GraphPad Prism version 7 for Mac (GraphPad Software, La Jolla, CA).
Results
All volunteers completed both study days, with the exception of one who withdrew after the first visit. The positioning of the catheter and infusion of isoosmolar and hyperosmolar saline solutions were well tolerated. None of the participants experienced vomiting, diarrhea, or other adverse effects.
Gastrointestinal perceptions
On the hyperosmolar infusion day, there was a mild increase in nausea scores (time, P , 0.0001; treatment, P = 0.081; treatment 3 time, P , 0.0001) (Fig. 1A) . None of the other parameters recorded changed significantly, although thirst seemed to increase after hyperosmolar saline (thirst: time, P , 0.0001; treatment, P = 0.077; treatment 3 time, P = 0.066) (Fig. 1B) .
Peptides and glucose
Mean plasma hormone ( Fig. 2A-2I ) and glucose (Fig. 2J) concentrations were comparable at baseline.
• Ghrelin: Plasma ghrelin concentrations gradually decreased with hyperosmolar, but not isoosmolar, saline infusion (time, P , 0.0001; treatment, P = 0.0007; treatment 3 time, P , 0.0001) (Fig. 2A) . The decline in ghrelin concentrations progressed after cessation of the infusion period, reaching a plateau that lasted beyond t = 180 minutes.
• CCK: Plasma CCK concentrations increased with hyperosmolar, but not isoosmolar, saline (time, P , 0.0001; treatment, P = 0.0042; treatment 3 time, P , 0.0001) from baseline (;0.5 pmol/L) to a peak at t = 30 minutes (;2 pmol/L), before returning to baseline (Fig. 2B ).
• GLP-1: Plasma GLP-1 concentrations increased (;t = 15/30 minutes) with hyperosmolar, but not isoosmolar, saline infusion, peaking at t = 60 minutes before returning to baseline at ;t = 120 minutes (time, P = 0.0018; treatment, P = 0.0004; treatment 3 time, P , 0.0001) (Fig. 2C ).
• GIP: Plasma GIP concentrations did not change with either of the infusions (time, P = 0.82; treatment, P = 0.025; treatment 3 time, P = 0.96) (Fig. 2D ).
• PYY: Plasma PYY concentrations (Fig. 2E) increased at the end of the hyperosmolar, but not isoosmolar, saline infusion (time, P , 0.0001; treatment, P , 0.0001; treatment 3 time, P , 0.0001), to a plateau that was maintained up until t = 180 minutes. The increase in PYY levels occurred after the CCK peak but after the initial decline in ghrelin levels. The curve for PYY concentrations appeared reciprocal to that of ghrelin.
• Glucagon: Plasma glucagon concentrations (Fig. 2F) increased at the end of the hyperosmolar, but not isoosmolar, saline infusion (time, P = 0.0016; treatment, P = 0.090; treatment 3 time, P , 0.0001), peaking at t = 60 minutes.
• NT: Although plasma NT concentrations were comparable at baseline (Fig. 2G) , they declined until t = 0 minutes (prior to initiation of infusion) on both days. Thereafter, NT concentrations increased (;t = 15/30 minutes) with hyperosmolar, but not isoosmolar, saline infusion (time, P , 0.0001; treatment, P = 0.0084; treatment 3 time, P , 0.0001), with significant differences at t = 30, 45, at 60 minutes.
• PP: Plasma PP concentrations remained relatively stable on both days, although there was a small, nonsignificant increase in plasma PP levels (Fig. 2H ) toward the end of the hyperosmolar infusion period (time, P = 0.13; treatment, P = 0.50; treatment 3 time, P = 0.62).
• Motilin: Plasma motilin concentrations (Fig. 2I) decreased slightly with no difference between infusions (time, P = 0.0002; treatment, P = 0.069; treatment 3 time, P = 0.92).
• Glucose: Plasma glucose levels were unchanged by either of the infusions (Fig. 2J) .
Cardiovascular parameters
The heart rate increased during the course of both days (Fig. 3A) . Infusion of hyperosmolar saline increased heart rate significantly when compared with isoosmolar saline (time, P , 0.0001; treatment, P = 0.0017; treatment 3 time, P = 0.0044). With regard to systolic and diastolic blood pressures, there was an effect of time, with a decline during the baseline period and an increase during the infusion and postinfusion period for both systolic blood pressure (time, P , 0.0001; treatment, P = 0.86; treatment 3 time, P = 0.52) (Fig. 3B) and diastolic blood pressure (time, P , 0.0001; treatment, P = 0.88; treatment 3 time, P = 0.27) (Fig. 3C) .
However, there was no treatment effect, with the changes being similar on both experimental days.
Discussion
As hypothesized, intraduodenal hyperosmolar saline suppressed plasma ghrelin concentrations. The magnitude of this suppression was substantial and comparable to that observed after a buffet meal (55) . This observation supports a role of intestinal osmolarity in the postprandial suppression of ghrelin secretion in humans, as recently reported for rats (24) . Whereas plasma ghrelin release was suppressed by the hyperosmolar infusion, plasma CCK, GLP-1, NT, glucagon, and PYY increased. Responses were comparable to postprandial responses (56) . GIP, PP, and motilin concentrations were unaffected, as was predictably the case for plasma glucose.
The time courses of the plasma hormone responses to hyperosmolar saline-CCK followed by NT and GLP-1, then glucagon and PYY-are consistent with the sequential recruitment that enteroendocrine cells posted along the length of the intestine. Ghrelin concentrations declined after the increase in CCK, coinciding with the increase in GLP-1 and NT, but occurring prior to the increase in PYY levels, which were delayed and longlasting, as would be consistent with exposure of the distal small intestine. CCK (41), GLP-1 (42), and PYY (43) are all known to slow gastric emptying, Figure 3 . Blood pressures (BP) and heart rate recorded in participants studied on two occasions during an intraduodenal infusion of either isoosmolar (300 mOsm/L) or hyperosmolar (1500 mOsm/L) saline. Data are means with SEM. Data were compared using repeated measurements two-way ANOVA. Post hoc tests were made using the Bonferroni correction. Two-sided P values of , 0.05 were considered significant (*). (A) Heart rate: time, P , 0.0001; treatment, P = 0.0017; treatment 3 time, P = 0.0044. (B) Systolic BP: time, P , 0.0001; treatment, P = 0.86; treatment 3 time, P = 0.52. (C) Diastolic BP: time, P , 0.0001; treatment, P = 0.88; treatment 3 time, P = 0.27. and this may also be the case for NT (57) , whereas intravenous ghrelin infusions have been reported to accelerate gastric emptying (3, 4) , indicating a potential reciprocal regulation of gastric emptying by ghrelin and the intestinal hormones.
In a previous study, hyperosmolar saline increased CCK (and GLP-1) concentrations comparably with 1 and 2 kcal/min intraduodenal glucose (supplemented with sodium chloride to attain similar osmolarity for all solutions). However, as that study did not include an isoosmolar control infusion, it is not possible to draw conclusions regarding a potential effect of hyperosmolarity (49) . Intravenous CCK has been reported to lower ghrelin and increase fasting PYY concentrations (58) . The observation that GLP-1 and NT release is abolished when nutrients are prevented from entering the distal small intestine (17) does not suggest a direct effect of CCK on GLP-1, NT, and PYY secretion.
If CCK mediates the effect of intraduodenal hyperosmolar saline, this may explain why hyperosmolar saline infused 40 to 50 cm distal to the ligament of Treitz had no effect on GLP-1 (enteroglucagon) or glucagon release (38) .
Whereas infusion of GLP-1 does not appear to affect ghrelin secretion (10, 58, 59) , PYY has been reported to lower basal plasma ghrelin concentrations (46) . Meanwhile, ghrelin concentrations were lowered comparably after CCK and CCK plus GLP-1 infusion, despite markedly higher PYY concentrations on the CCK infusion day (58, 60) .
The marginal increase in PP, a hormone predominantly under vagal control (61), indicates minimal cholinergic reflex activation by hyperosmolar saline, and it suggests that peptides released in response to hyperosmolar content are not strong stimuli for PP secretion.
The decline in ghrelin concentrations, as well as stimulation of multiple anorexigenic gut peptides, was not associated with major effects on appetite, as evaluated by VASs (50) . The nasoduodenal catheter might have affected the desire to eat, but on every VAS questionnaire participants consistently indicated that they would eat if served food. There were small increases in scores for nausea and thirst; the latter is not surprising in the light of the extra salt load provided by the hyperosmolar infusion. Nausea might have been elicited either by activation of vagal or sympathetic afferents, or by the collective hormonal response.
It is worth considering whether nausea influences the release of ghrelin. PYY infusions have been reported to lower ghrelin levels (46) , but the PYY dose (0.8 pmol/kg/ min) used for that and later studies is associated with nausea (62-64) and an increase in heart rate (63). Coinfusion of PYY and GLP-1, resulting in more robust suppression of ghrelin concentrations than observed during infusion of PYY alone, is also associated with nausea and increased heart rate (59). Furthermore, infusion of CCK, associated with lowering of ghrelin secretion and stimulation of PYY, is also associated with nausea (58, 60) . The observed decrease in ghrelin and increase in glucagon concentrations might reflect an increase in sympathetic tone (or lowering of vagal tone) due to fluid shifts into the intestine, or nausea, and/or may represent a countermeasure to maintain glucose levels at basal values.
The increase in heart rate during hyperosmolar saline infusion is comparable to postprandial changes in healthy individuals (65) .
We measured total plasma ghrelin, rather than just the acylated fraction, because we think that this approach best captures changes in ghrelin secretion. Although acylated ghrelin measurements may provide more information about hormone action, postprandial changes in total ghrelin have previously been found to mirror changes in acylated ghrelin (66, 67) .
As we only studied the effects of saline solutions, it is not possible to say whether the outcomes can be generalized to other hyperosmolar solutions (24) . Furthermore, we did not study the dose response of hyperosmolar solutions. The osmolarity of our hyperosmolar solution was similar to (1) solutions used in the rat study that inspired this study (24) , (2) solutions used in a previous tube study (18) , and (3) the osmolarity of glucose solutions used for oral glucose tolerance tests. It would be interesting to pursue the potential effect of hyperosmolar solutions on ad libitum food intake in future studies.
Conclusion
Proximal small intestinal hyperosmolarity, resulting from infusion of hyperosmolar saline, lowers circulating ghrelin concentrations in humans to a degree comparable to changes observed after meal ingestion. Concurrent with the reduction in total ghrelin concentrations, there are elevations in a range of other gut peptides. Osmolarity should be considered when interpreting the existing literature and when comparing the effects of nutrients and chemicals on gut hormone secretion in future studies. Author Contributions: S.V. conceived the study and drafted the study design, recruited participants, collected data, carried out peptide measurements, performed statistical analyses, prepared figures, and drafted the manuscript; J.F.R. measured CCK and interpreted the data; M.B. and J.G. were involved in the recruitment of participants and data collection; T.W., C.F.D., B.H., M.H., C.K.R., and J.J.H. were involved in the design of the study and data interpretation. All authors critically reviewed the manuscript and have approved the publication of this final version of the manuscript.
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